These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 7546811)

  • 41. Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson's disease.
    Hauser RA; Holford NH
    Mov Disord; 2002 Sep; 17(5):961-8. PubMed ID: 12360545
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Outcome prediction of enteral levodopa/carbidopa infusion in advanced Parkinson's disease.
    Westin J; Nyholm D; Groth T; Dougherty MS; Yerramsetty PK; Palhagen SE
    Parkinsonism Relat Disord; 2006 Dec; 12(8):509-13. PubMed ID: 16731025
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease.
    Metman LV; Blanchet PJ; de Jong D; Mouradian MM; Chase TN
    Mov Disord; 1996 May; 11(3):257-60. PubMed ID: 8723141
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Aggravation of Parkinson's disease after inadequate use of levodopa in controlled-release preparations].
    Mateo D; Dobato JL; Giménez-Roldán S
    Neurologia; 1995 Jan; 10(1):7-13. PubMed ID: 7893519
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long term bromocriptine treatment in de novo parkinsonian patients.
    Herskovits E; Yorio A; Leston J
    Medicina (B Aires); 1988; 48(4):345-50. PubMed ID: 3076200
    [No Abstract]   [Full Text] [Related]  

  • 46. Clinical efficacy of a single afternoon dose of effervescent levodopa-carbidopa preparation (CHF 1512) in fluctuating Parkinson disease.
    Stocchi F; Fabbri L; Vecsei L; Krygowska-Wajs A; Monici Preti PA; Ruggieri SA
    Clin Neuropharmacol; 2007; 30(1):18-24. PubMed ID: 17272966
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
    Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Soft tissue-anchored transcutaneous port attached to an intestinal tube for long-term gastroduodenal infusion of levodopa/carbidopa in Parkinson disease.
    Nyman R; Lundgren D; Nyholm D
    J Vasc Interv Radiol; 2009 Apr; 20(4):500-5. PubMed ID: 19216094
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Randomized trial of pallidotomy versus medical therapy for Parkinson's disease.
    Vitek JL; Bakay RA; Freeman A; Evatt M; Green J; McDonald W; Haber M; Barnhart H; Wahlay N; Triche S; Mewes K; Chockkan V; Zhang JY; DeLong MR
    Ann Neurol; 2003 May; 53(5):558-69. PubMed ID: 12730989
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Treatment of parkinson disease with the combination of L-dopa (plus carbidopa) and trazodone].
    Piccinin GL; Piccirilli M; Agostini L
    Clin Ter; 1981 Mar; 96(6):621-6. PubMed ID: 7285527
    [No Abstract]   [Full Text] [Related]  

  • 51. [Therapeutic effect of the temporary interruption of treatment of long-term parkinsonian patients: role of the peripheral metabolism of L-DOPA].
    García García B; Hernández Calzadilla C; Barajas García-Talavera F; Fernández Martín F; Pérez de Paz A; Rodríguez Díaz M
    Arch Neurobiol (Madr); 1986; 49(3):145-52. PubMed ID: 3741052
    [No Abstract]   [Full Text] [Related]  

  • 52. [Value of low-dose dopa therapy in Parkinson disease].
    Petit H; Rousseaux M; Mazingue A; Warot P
    LARC Med; 1983; 3(7):514-6. PubMed ID: 6645742
    [No Abstract]   [Full Text] [Related]  

  • 53. Sinemet - 25/100.
    Med Lett Drugs Ther; 1980 Jun; 22(12):51. PubMed ID: 7374623
    [No Abstract]   [Full Text] [Related]  

  • 54. Drug holiday and management of Parkinson disease.
    Weiner WJ; Koller WC; Perlik S; Nausieda PA; Klawans HL
    Neurology; 1980 Dec; 30(12):1257-61. PubMed ID: 7192805
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Letter: Ascorbic acid in levodopa therapy.
    Sacks W; Simpson GM
    Lancet; 1975 Mar; 1(7905):527. PubMed ID: 47001
    [No Abstract]   [Full Text] [Related]  

  • 56. Bromocriptine in parkinsonism. A long-term study.
    Lees AJ; Haddad S; Shaw KM; Kohout LJ; Stern GM
    Arch Neurol; 1978 Aug; 35(8):503-5. PubMed ID: 666607
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Long-term treatment of tardive dyskinesia with presynaptically acting dopamine-depleting agents.
    Fahn S
    Adv Neurol; 1983; 37():267-76. PubMed ID: 6858776
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Drug therapy of Parkinsonism dopaminergic drugs.
    Bianchine JR
    Ohio State Med J; 1977 Feb; 73(2):84-5. PubMed ID: 834419
    [No Abstract]   [Full Text] [Related]  

  • 59. Short- and long-term approaches to the "on-off" phenomenon.
    Papavasiliou PS; Cotzias GC; Mena I
    Adv Neurol; 1974; 5():379-86. PubMed ID: 4440585
    [No Abstract]   [Full Text] [Related]  

  • 60. [The combination of L-dopa and carbidopa in therapy of a case of familial juvenile parkinsonism].
    Piccirilli M; Piccinin GL; La Medica A
    Clin Ter; 1981 Feb; 96(3):335-40. PubMed ID: 7307449
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.